Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

Intellipharmaceutics Announces Launch Of Generic Seroquel XR

Published 06/06/2017, 10:54 PM
Updated 07/09/2023, 06:31 AM
AZN
-
ENDPQ
-
IPCIh
-
AZN
-
MNKKQ
-

Intellipharmaceutics International Inc. (TO:IPCI) announced the launch of a generic version of schizophrenia drug, Seroquel XR by its marketing and distribution partner in the U.S, Mallinckrodt Public Limited Company (NYSE:MNK) .

The launch was preceded by FDA approval of the company’s abbreviated new drug application (ANDA) in May 2017.

Astrazeneca (LON:AZN) plc’s (NYSE:AZN) Seroquel XR is indicated for use in the treatment of schizophrenia and bipolar disorder.

The drug was launched as extended-release tablets for all strengths including 50, 150, 200, 300 and 400 mg. Total sales in the U.S. for Seroquel XR, in both branded and generic version, was $842 million for the 12 months ended Apr 2017. We believe that the launch in the U.S. will further boost the performance of Intellipharmaceutics’ generics business.

IntelliPharmaCeutics’ shares gained 8.16% following the announcement. However, the stock has underperformed the Zacks classified Medical - Drugs industry so far this year. The company’s shares lost 25.4%, while the industry registered an increase of 4.9%.

In Oct 2016, Intellipharmaceutics entered into a license and commercial supply agreement with Mallinckrodt, granting the latter an exclusive license to market, sell and distribute generic Seroquel XR, Pristiq and Lamictal XR in the U.S., for which it had filed abbreviated new drug applications (NDAs). The generic versions of Pristiq and Lamictal are currently under review.

Meanwhile, the generic version of Seroquel XR is already marketed by some major pharma companies like Endo International PLC (NASDAQ:ENDP) , India-based Lupin Ltd., as well as by some smaller companies. Hence, Intellipharmaceutics will face tough competition as far as its commercialization is concerned.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Moreover, in May 2017, Intellipharmaceutics had announced that its partner Par Pharmaceutical launched 10 and 20 mg strengths of its marketed generic version of Focalin XR capsules. The generic version was available in 15, 25, 30 and 35 mg strengths prior to the launch.

Intellipharmaceutics specializes in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company has also filed NDA 505(b)(2) for its specialty drug product candidates in development including Rexista, an abuse-deterrent oxycodone product and Regabatin XR, a neuropathic pain management product.

Zacks Rank

IntelliPharmaCeutics currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

3 Stocks to Ride a 588% Revenue Explosion

At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...

By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early.

See Zacks' Top 3 Stocks to Ride This Space >>



Astrazeneca PLC (AZN): Free Stock Analysis Report

Endo International PLC (ENDP): Free Stock Analysis Report

Intellipharmaceutics International Inc. (IPCI): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Mallinckrodt PLC (MNK): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.